Protective role of TRPV1+ nociceptive neurons communication to macrophages against T. cruzi infection in mice Authors: Sergio M. Borghi, Aparecida D. Malvezi, Maria Isabel Lovo-Martins, Victor Fattori, Tiago H. Zaninelli, Mariana M. Bertozzi, Camila R. Ferraz, Thiago M. Cunha, Rubia Casagrande, Marli C. Martins-Pinge, Phileno Pinge-Filho, Waldiceu A. Verri Published: 2024 ABSTRACT Chagas’ disease is a life-threatening condition caused by Trypanosoma cruzi. Patients with chronic disease may develop gastrointestinal, neurological, or associated neuro-digestive dysfunctions. CNS invasion by T. cruzi can occur in the acute phase, and its presence in the brain and cerebrospinal fluid was reported. T. cruzi induces nociceptor neuron activation and pain. Nociceptive neurons and macrophage interact in diseases, and this neuroimmune communication has a pivotal role in disease outcome. We investigated, the role of TRPV1+ neurons in experimental T. cruzi infection in mice. T. cruzi forms were observed in the DRG and spinal cord in early stages of acute infection, and intrathecal administration of T. cruzi antigens into spinal cord induced pain. Trpv1 mRNA expression was increased in the DRG of infected mice and targeting TRPV1 reduced T. cruzi-induced pain. TRPV1 nociceptor ablation increased blood parasitemia while TRPV1 knockout mice presented 50% mortality upon infection in a normally non-lethal model. TRPV1 knockout also worsened clinical outcomes (hepatomegaly and megacecum), increased plasmatic Th2 cytokines and nitrite in cardiac tissue, and reduced heart leukocyte infiltration. Conditioned media of capsaicin-stimulated DRG neurons decreased macrophage internalization of T. cruzi, and CGRP receptor antagonism in infected mice reduced pain, increased early parasitemia and promoted 18% mortality. This indicates that soluble mediators released upon nociceptor activation such as CGRP increase macrophage ability to control disease outcome. These data unveil TRPV1+ neurons release CGRP to limit macrophage internalization of T. cruzi, triggering protective mechanisms against T. cruzi infection. Introduction Transient receptor potential vanilloid member 1 (TRPV1) is a cation channel that is calcium permeable and belongs to the TRP channel superfamily, an evolutionary group of conserved integral membrane proteins (Samanta et al., 2018). It was originally described in nociceptor neurons, responsible for sensing noxious mechanical, heat or vanilloids stimuli (Caterina et al., 1997), being a key element in pain generation/persistence (Devesa et al., 2014). TRPV1 is expressed by peptidergic C-fibers, and its activation induces the release of the neuropeptides such as calcitonin-gene related peptide (CGRP). In turn, CGRP is crucial for algesic exocytotic mobilization of TRPV1 in peptidergic C-fibers (Devesa et al., 2014). TRPV1 is also described to be expressed in macrophages (Joe and Lokesh, 1994; Lv et al., 2021), which express CGRP receptors with functional consequences (Fernandez et al., 2001; Ichinose and Sawada, 1996; Zaninelli et al., 2022). This implicates TRPV1 as crucial signaling protein during neuro-immune interactions. Chagas’ disease (CD) is an anthropozoonosis caused by the protozoan Trypanosoma cruzi. An estimated 6 to 7 million people have CD worldwide, especially in Latin America (WHO, 2023), representing a neglected public health condition with high morbimortality (Lidani et al., 2019). CD chronic phase is characterized by relevant heart, digestive, and/or neurological manifestations as well as the absence of all these alterations (Nguyen and Waseem, 2023). Human central nervous system (CNS) may be affected in the acute phase; however, CNS involvement is especially observed in the chronic phase. In preclinical studies, T. cruzi infection with varied strains induce pain (Borghi et al., 2020; Cangussu et al., 2013). While pain response has been characterized, the involvement of nociceptors for infection control in CD has yet to be explored. Since nociceptors sense environmental cues and neuronal signals can shape the immune response (Pinho-Ribeiro et al., 2017), we hypothesize that neuroimmune communication plays a role during CD. For that, we investigated the role of TRPV1 using genetic and pharmacological approaches in a mouse model of CD-associated hyperalgesia and neuroinflammation. Materials and methods Materials and methods are detailed described in the supplementary data. Results T. cruzi infects DRG neurons and spinal cord We sought to determine whether during mouse infection, parasites could be found in the nervous system. From 7 to 21 days after T. cruzi inoculation, parasitemia was detected in blood of mice in time-decreasing counts (Fig. 1A). Interestingly, this event was accompanied by the detection of T. cruzi in DRG (7–21 days) and spinal cord (SC; 7–14 days) samples (Fig. 1B and C, respectively). Fig. 1D shows the representative images of T. cruzi forms detected on the 7th day post-infection. Trypomastigote was found free in samples of DRG and spinal cord, and amastigote nests were found inside the spinal cord. Tissue homogenates were used because this is a common approach to assess the presence of trypomastigote in fresh samples, but as a drawback, we were unable to determine in which cell types the parasites were inside. Nevertheless, previous evidence demonstrates T. cruzi can infect spinal cord astrocytes, microglia, and macrophages (Borghi et al., 2020).Fig. 1Course of experimental T. cruzi infection in WT mice and evaluation of the role of Tc-Ag and TRPV1 in T. cruzi-induced pain. A) Blood parasitemia (7–28 days). B) % of DRG samples positive for T. cruzi (7–28 days). C) % of spinal cord samples positive for T. cruzi (7–28 days). D) Representative images of the parasites in DRG and spinal cord (SC) (7th day post-infection; 40x scale bar, 100 μm). E and F) Mechanical and thermal thresholds evaluation after i.t. injection of Tc-Ag (1–144 h post-treatment). G) Trpv1 mRNA expression upon i.t. treatments with glial and NFκB inhibitors (7th day post-infection). H-K) Mechanical and thermal thresholds (1–7 h post-treatment), blood parasitemia (7th h post-treatment), and survival rate (7th day post-infection) upon i.t. treatment with TRPV1 antagonist. n = 5–9 mice per group. Results are presented as mean + SEM. ƒ < 0.05 relative to 14, 21, and 28 days, ∗p < 0.05 relative to control non-infected group, #p < 0.05 relative to vehicle-treated infected animals.Fig. 1 Course of experimental T. cruzi infection in WT mice and evaluation of the role of Tc-Ag and TRPV1 in T. cruzi-induced pain. A) Blood parasitemia (7–28 days). B) % of DRG samples positive for T. cruzi (7–28 days). C) % of spinal cord samples positive for T. cruzi (7–28 days). D) Representative images of the parasites in DRG and spinal cord (SC) (7th day post-infection; 40x scale bar, 100 μm). E and F) Mechanical and thermal thresholds evaluation after i.t. injection of Tc-Ag (1–144 h post-treatment). G) Trpv1 mRNA expression upon i.t. treatments with glial and NFκB inhibitors (7th day post-infection). H-K) Mechanical and thermal thresholds (1–7 h post-treatment), blood parasitemia (7th h post-treatment), and survival rate (7th day post-infection) upon i.t. treatment with TRPV1 antagonist. n = 5–9 mice per group. Results are presented as mean + SEM. ƒ < 0.05 relative to 14, 21, and 28 days, ∗p < 0.05 relative to control non-infected group, #p < 0.05 relative to vehicle-treated infected animals. T. cruzi antigens (Tc-Ag) induce mechanical and thermal hyperalgesia We had previously demonstrated that T. cruzi infection induces hyperalgesia (Borghi et al., 2020). As we observed the presence of T. cruzi in DRG neurons and spinal cord, we next wonder whether T. cruzi-derived products can directly sensitize spinal cord to induce hyperalgesia. We used intrathecal injection of Tc-Ag to determine whether these antigens can produce hyperalgesia by itself in non-infected animals. Tc-Ag (0.009–0.9 μL) significantly lowered mechanical (Fig. 1E) and thermal thresholds (Fig. 1F), indicating that T. cruzi antigens can directly induce pain in non-infected animals. These results indicate that T. cruzi antigens can induce hyperalgesia. T. cruzi increases DRG Trpv1 mRNA and targeting TRPV1 enhances mechanical and thermal thresholds reduced during the infection On the 7th day post-infection (time-period defined previously; Borghi et al., 2020), T. cruzi infection increased the DRG Trpv1 mRNA expression and intrathecal pharmacological blockage of spinal cord glial cells astrocytes (α-amd; 100 nmol) and microglia (mino; 150 μg), and NFκB (PDTC; 300 μg) rescued this change (Fig. 1G). Thus, T. cruzi infection up-regulates DRG Trpv1 mRNA expression by a mechanism that was sensitive to pharmacological strategies targeting glial cells and also NFkB, which is activated in both glial cells and neurons in this infection (Borghi et al., 2020). In corroboration, intrathecal treatment with AMG9810 (a potent and selective cinnamide TRPV1 antagonist; 10–100 nmol) increased mechanical and thermal thresholds (Fig. 1H and I, respectively), indicating that pharmacological blockade of TRPV1 reduces T. cruzi infection-associated hyperalgesia. However, the pharmacological blockade of TRPV1 with intrathecal AMG9810 did not interfere with parasitemia and survival rate in an acute intervention protocol (until 7 days after the infection) (Fig. 1J and K, respectively). Therefore, treatment with the TRPV1 antagonist AMG9810 by intrathecal route and tested doses, did not interfere with T. cruzi infection parasitemia and mortality outcomes, although it interrupted hyperalgesia, at least, during the 7 h of measurements. Evaluation of the effects of different approaches for TRPV1 silencing during experimental T. cruzi infection We applied a pharmacological denervation of TRPV1+ neurons by using neonatal treatment with capsaicin (Heffner et al., 2014) (Fig. 2A–E). Successful partial denervation was demonstrated through increased thermal threshold, reduced DRG Calca mRNA expression, and decreased DRG TRPV1 expression by immunofluorescence analyzes (Fig. 2A). Infected capsaicin-denervated group also showed reduced mechanical (from 4 to 28 days) and thermal (from 8 to 28 days) hyperalgesia relative to their non-denervated infected pairs (Fig. 2B and C, respectively), and higher blood parasite levels (days 7 and 14; Fig. 2D), however, without deaths during the whole period (Fig. 2E).Fig. 2Effects of different approaches targeting TRPV1 and CGRP during experimental T. cruzi infection. A) Thermal threshold, Calca mRNA expression, and TRPV1 fluorescence staining (40x scale bar, 100 μm) for confirmation of capsaicin denervation of TRPV1+ nociceptor neurons. B-E) Mechanical and thermal thresholds (0–28 days post-infection), blood parasitemia (7–28 days), and survival rate (0–28 days post-infection) evaluations for capsaicin denervation of TRPV1+ nociceptor neurons). F-I) Mechanical and thermal thresholds (0–28 days post-infection), blood parasitemia (7–28 days), and survival rate (0–28 days post-infection) evaluations for TRPV1 genetic deletion (TRPV1−/−). J and K) Representative images of macroscopic analyzes of abdominal organs (liver and cecum; 1 cm) and quantification of the percentage of organ weight relative to the animal weight. L and M) % of macrophage internalization index and % of cell viability. N-Q) Mechanical and thermal thresholds (0–28 days post-infection), blood parasitemia (7–28 days), and survival rate (0–28 days post-infection) evaluations for CGRP receptor, RAMP1, antagonist treatment (BIBN4096BS). n = 9–11 mice per group. Results are presented as mean + SEM. ∗p < 0.05 relative to control non-infected group, #p < 0.05 relative to vehicle-treated infected animals. Vertical black lines separate the steps of capsaicin denervation (left), TRPV1 deficiency (center), and in vitro/in vivo experiments evaluating the role of CGRP (right).Fig. 2 Effects of different approaches targeting TRPV1 and CGRP during experimental T. cruzi infection. A) Thermal threshold, Calca mRNA expression, and TRPV1 fluorescence staining (40x scale bar, 100 μm) for confirmation of capsaicin denervation of TRPV1+ nociceptor neurons. B-E) Mechanical and thermal thresholds (0–28 days post-infection), blood parasitemia (7–28 days), and survival rate (0–28 days post-infection) evaluations for capsaicin denervation of TRPV1+ nociceptor neurons). F-I) Mechanical and thermal thresholds (0–28 days post-infection), blood parasitemia (7–28 days), and survival rate (0–28 days post-infection) evaluations for TRPV1 genetic deletion (TRPV1−/−). J and K) Representative images of macroscopic analyzes of abdominal organs (liver and cecum; 1 cm) and quantification of the percentage of organ weight relative to the animal weight. L and M) % of macrophage internalization index and % of cell viability. N-Q) Mechanical and thermal thresholds (0–28 days post-infection), blood parasitemia (7–28 days), and survival rate (0–28 days post-infection) evaluations for CGRP receptor, RAMP1, antagonist treatment (BIBN4096BS). n = 9–11 mice per group. Results are presented as mean + SEM. ∗p < 0.05 relative to control non-infected group, #p < 0.05 relative to vehicle-treated infected animals. Vertical black lines separate the steps of capsaicin denervation (left), TRPV1 deficiency (center), and in vitro/in vivo experiments evaluating the role of CGRP (right). We also investigated the effect of genetic deletion (−/−) of TRPV1 and compared to TRPV1 denervation. T. cruzi induced increases in Th1/Th17 cytokines, TNF-α, IFN-γ, IL-6, IL-2, and IL-17A in WT mice, while TRPV1−/− or TRPV1 neuronal denervation reduced only TNF-α levels (Figs. S1A–E). Regarding Th2 cytokines, in infected WT mice, IL-4 but not IL-10 increases significantly when compared to non-infected mice, and infected TRPV1−/− mice presented significant increases in both IL-4 and IL-10, whereas in capsaicin-denervated mice, significant elevation was just observed in IL-10 relative to WT mice (Figs. S1F and G). T. cruzi leads to increased production of NO in plasma and heart samples of WT mice, and in TRPV1−/− mice, but not capsaicin-denervated mice, in which the NO concentration was further increased relative to WT mice (Figs. S1H and I). Finally, in TRPV1−/− mice, inflammatory infiltration was markedly reduced relative to WT, which was not observed in capsaicin-denervated mice (Figs. S1J–N). Altogether, these data evidenced that TRPV1 deficiency promoted a more profound modulatory effect over immune function in T. cruzi infection compared to that observed with TRPV1 partial denervation. In agreement with such conclusion, infected TRPV1−/− mice showed reduction of mechanical (from 4 to 28 days) and thermal (from 2 to 28 days) hyperalgesia relative to their WT infected pairs (Fig. 2F and G, respectively) and higher blood parasitemia (days 7, 14, and 18; Fig. 2H). Unexpectedly, lower survival rates from day 18 onwards were observed in infected TRPV1−/− mice compared to infected WT controls (⁓48% of deaths vs no deaths on WT group on day 28; Fig. 2I). Further corroborating with the rationale of a more severe disease in infected TRPV1−/− mice, significant hepatomegaly and megacecum (Fig. 2J and K) were observed compared to control non-infected mice while there was no significant induction of hepatomegaly and megacecum comparing non-infected and infected mice (Fig. 2J and K). Since we observed increased mortality in TRPV1−/− mice, we next questioned whether TRPV1+ neurons-derived molecules could modify macrophage function using as a readout its ability to internalize T. cruzi (Fig. 2L and M). We standardized the volume of neuronal conditioned media by the CGRP concentration. CGRP was selected as an example of a neuropeptide produced by TRPV1+ neurons that can modulate immune cell function (Chiu et al., 2013; Fattori et al., 2019; Zaninelli et al., 2022). Naïve DRG neurons from WT and TRPV1−/− mice were cultured and stimulated with capsaicin (a TRPV1 agonist). Capsaicin could not induce CGRP release by TRPV1−/− DRG neurons while WT DRG neurons were found to significantly increase CGRP in the culture media (Fig. S2). A concentration range between 0.5 and 4.5 pg/mL of CGRP in the conditioned DRG neurons culture media was used to stimulate macrophages. The highest concentrations of CGRP impaired bone-marrow derived macrophage (BMDM) internalization of T. cruzi (Fig. 2L). Cell viabilities were unchanged in cultured macrophages (Fig. 2M). These results indicate a protective role of TRPV1+ neurons in T. cruzi infection because parasite internalization by macrophages is a mechanism used by T. cruzi for dissemination and to reach other target organs for successful infection. At this point, our interpretation was that the activation of TRPV1+ neurons induced the release of CGRP that in turn would reduce the entry of T. cruzi in macrophages limiting the development of disease. Thus, TRPV1+ neurons participate in T. cruzi-induced pain, but also regulate immunity as in the case of macrophages affecting the disease phenotype depending on the level of TRPV1 deficiency. Effects of CGRP receptor, RAMP1, antagonism during experimental T. cruzi infection in mice Considering the data obtained in the last in vitro experimental approach, the outcomes of CGRP receptor antagonism in mice upon experimental T. cruzi infection were evaluated (Fig. 2N–Q). Mice were treated with the selective antagonist of the CGRP receptor RAMP1 (Doods et al., 2000; Hay et al., 2002), BIBN4096BS (Olcegepant, 5 mg/kg; intraperitoneal; once every three days) (Pinho-Ribeiro et al., 2018). Infected WT mice treated with BIBN4096BS presented reduced mechanical (from 4 to 28 days) and thermal (from 6 to 28 days) hyperalgesia relative to their vehicle-treated infected pairs (Fig. 2N and O, respectively). BIBN4096BS-treated mice also presented higher blood parasite levels at days 7 and 14 post-infection (Fig. 2P). Regarding mortality rate, 18% of mice died on day twenty-six of the experimental protocol. On the other hand, non-infected animals receiving the same BIBN4096BS treatment regimen did not die, indicating that the mortality was not due to BIBN4096BS treatment itself (Fig. S3), but rather by the inhibition of CGRP/RAMP1 signaling during T. cruzi infection (Fig. 2Q). These data demonstrate CGRP plays a role in hyperalgesia and host ability to deal with experimental T. cruzi infection corroborating the in vitro data of Fig. 2L–M. Discussion In humans CD acute stage, tissue parasitism can be detected in sciatic nerve, heart neuronal ganglia, Schwann cells, and enteric glia (Buckner et al., 1999; Chuenkova and Pereiraperrin, 2010). T. cruzi can also infect CNS neuronal and non-neuronal cells in the brain and neuropil (Buckner et al., 1999; Da Mata et al., 2000; Useche et al., 2022) as well as the cerebrospinal fluid (Escarrá et al., 2018; Hoff et al., 1978). The present study identifies for the first-time free trypomastigotes in DRG and spinal cord samples, suggesting in fact, that T. cruzi might infect nervous tissue which might lead to pain. We show that TRPV1 deficiency (full genetic deficiency or capsaicin partial denervation) increased blood parasitemia and mortality in TRPV1−/− when compared to WT mice. This result indicates a host protective role of TRPV1+ neurons in T. cruzi infection. Moreover, the conditioned media of capsaicin-stimulated neurons containing CGRP reduced T. cruzi internalization by macrophages as well as the antagonism of CGRP receptor, RAMP1, increased blood parasitemia and mortality rate in infected mice. These results are in line with the interpretation that the activation of TRPV1+ neurons during T. cruzi infection is not only responsible for hyperalgesia, but also for shaping the immune response via neuropeptides such as CGRP promoting host protection. The present findings corroborate evidence that CGRP is, in most cases, an essential neuropeptide in the neuro-immune communication in disease though the phenotypic outcomes will depend on the disease scenario (Chiu et al., 2013; Fattori et al., 2021). We found that both TRPV1−/− or capsaicin-denervated mice presented similar impaired immune response against T. cruzi., and these two approaches resulted in lower TNF-α production in infected mice, a crucial cytokine for trypanocidal effects (Silva et al., 1995). Although not significant, other important Th1 (IFN-γ/IL-2)/Th17 (IL-17) cytokines related to infection resistance (Miyazaki et al., 2010; Tarleton, 1988; Torrico et al., 1991) were down-regulated in both approaches. Th2 cytokines (IL-4/IL-10) are associated with defective protective immunity and increased susceptibility to T. cruzi infection (Jha et al., 2020). Capsaicin denervation and more pronouncedly TRPV1 deficiency increased Th2 cytokine levels and reduced leukocyte infiltration into the heart. These data align with increased mortality in TRPV1−/− mice. Another unexpected result was elevated nitrite production in TRPV1−/− plasma and heart tissues relative to WT and capsaicin-denervated WT, which seem a contradiction with impaired Th1 response in this group. Nevertheless, apparently, TRPV1−/− did not affect the intra-cellular killing machinery of macrophages. It is likely that as TRPV1 deficiency increased the parasitemia, in this scenario, macrophages trend to internalize more parasites, the nitrite production is increased in parallel. In Staphylococcus aureus infection, the activation of nociceptors induces the release CGRP, which reduces macrophage production of TNF-α (Chiu et al., 2013). TRPV1 deficiency or denervation also reduced T. cruzi-induced production of TNF-α. Further in the S. aureus infection, Nav1.8 neuronal deletion (part of these neuronal population is TRPV1+ and CGRP+) (Patil et al., 2018) and CGRP reduced the cellularity in the lymph nodes of mice (Chiu et al., 2013). In a model of Streptococcus pyogenes necrotizing infection, streptolysin S acted as a virulence factor activating TRPV1+ neurons to release CGRP. This neuropeptide reduced the recruitment of protective neutrophils (Pinho-Ribeiro et al., 2018). Both studies indicate that TRPV1-derived neuropeptides such as CGRP can sabotage the immunity against infectious agents by affecting immune cell function. Given the role of TRPV1 in disease phenotype in T. cruzi infection, we further pursued to understand the role of TRPV1 neurons-derived CGRP that could explain its role in disease. Quite interestingly, TRPV1+ neurons-derived CGRP presented a protective role in T. cruzi infection contrasting to their detrimental role observed in bacterial infections (Chiu et al., 2013; Pinho-Ribeiro et al., 2018). To reach this conclusion, DRG neurons were stimulated with capsaicin, which induced CGRP release. The CGRP enriched conditioned media reduced the internalization of T. cruzi by macrophages. A control conditioned media obtained from TRPV1−/− mice DRG neurons stimulated with capsaicin had no activity in macrophage internalization of T. cruzi. Macrophage represents a cell with important trypanocidal mechanisms, however, T. cruzi may evade such mechanisms and use this phagocyte to replicate inside of it. Thus, increased internalization of parasites by macrophage has detrimental effects and is part of T. cruzi life cycle and tissue tropism (Malvezi et al., 2014; Martin-Escolano et al., 2022). In addition to the in vitro studies, in vivo, mechanical and thermal hyperalgesia induced by T. cruzi infection were successfully diminished by approaches targeting TRPV1+ neurons and CGRP/RAMP-1 signaling, which indicate the participation of TRPV1+ neurons-derived CGRP in experimental CD hyperalgesia. The hyperalgesia observed in T. cruzi infection involves nociceptor neuron activation, however, the role of these cells is broader than nociceptive signaling. TRPV1+ neurons presented a role in the resistance to T. cruzi infection by releasing CGRP, which in turn, diminished parasite entry in macrophages, thus, limiting disease development. In fact, the TRPV1 full deficiency resulted in ⁓50% lethality in an experimental protocol that normally progresses without lethality. There are instances in which genetic deletion may present outcomes unrelated to the target (Ghosh et al., 2021). Thus, a second approach was used to confirm the concept brought by the results using TRPV1−/− mice. The partial denervation of TRPV1+ neurons using capsaicin neonatal treatment mimicked most of TRPV1 deletion outcomes except by the lethality. The degree of TRPV1 function impairment of full genetic deletion versus partial TRPV1 denervation might be the main explanation for such differences. In fact, capsaicin-denervation protocol in rodents causes a loss of ⁓50% of the TRPV1+/CGRP+ DRG neurons (Hiura, 2000; Martinez-Martinez et al., 2011). Using a third approach, in addition to reduction of hyperalgesia, 18% lethality was observed with the treatment of infected mice with BIBN4096BS, an antagonist of the CGRP receptor, RAMP1 (Doods et al., 2000; Hay et al., 2002). Importantly, the lethality was unrelated to the treatment itself because uninfected animals treated with BIBN4096BS presented 100% survival in the same protocol. Interestingly, there was a titrated effect in lethality with 48% in TRPV1−/− mice, 18% by RAMP1 antagonist, and 0% by capsaicin partial denervation of TRPV1 neurons. These results might reflect the titrated functional loss of TRPV1+ neurons communication with immune cells through CGRP release by each approach, and that additional neuropeptides may account to the host protection provided by TRPV1+ neurons (Fattori et al., 2021), therefore, the most striking phenotype was observed in TRPV1−/− mice. Concluding, targeting TRPV1 reduces T. cruzi infection hyperalgesia, and TRPV1+ nociceptors provide beneficial effects to the host during infection. TRPV1 knockout mice exhibited higher lethality as well as changes on important trypanocidal cytokines such as TNF-α. Moreover, the CGRP enriched conditional media of capsaicin-stimulated DRG neurons reduced T. cruzi internalization in vitro. In vivo, the antagonism of the CGRP receptor, RAMP1, increased blood parasitemia. Thus, TRPV1+ nociceptor neurons acting via neuropeptide release are important for T. cruzi infection control. Although the present data do not exclude the contribution of other molecules (including other neuropeptides) on the regulation of parasitemia outcome, in vitro and in vivo experiments demonstrate that CGRP is at least one of the neuronal products mediating the neuro-immune communication in experimental CD, which to our knowledge, was previously unknown. Summing up, we have unveiled a hitherto unrecognized neuro-immune interaction mechanism in Chagas disease. Fig. S4 summarizes our findings. CRediT authorship contribution statement Sergio M. Borghi: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review & editing. Aparecida D. Malvezi: Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – review & editing. Maria Isabel Lovo-Martins: Data curation, Formal analysis, Investigation, Methodology, Resources, Writing – review & editing. Victor Fattori: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing. Tiago H. Zaninelli: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing. Mariana M. Bertozzi: Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing. Camila R. Ferraz: Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing. Thiago M. Cunha: Funding acquisition, Resources, Writing – review & editing. Rubia Casagrande: Data curation, Formal analysis, Funding acquisition, Resources, Writing – review & editing. Marli C. Martins-Pinge: Data curation, Formal analysis, Funding acquisition, Resources, Writing – review & editing. Phileno Pinge-Filho: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing. Waldiceu A. Verri: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.